Broadfin Capital Initiates New Positions In Corium International Inc (CORI), AMAG Pharmaceuticals Inc. (AMAG) and La Jolla Pharmaceutical Company (LJPC)

In three recent filings,  Kevin Kotler’s Broadfin Capital has revealed adding three companies: Corium International Inc (NASDAQ:CORI), AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) and La Jolla Pharmaceutical Company (NASDAQ:LJPCto its equity portfolio.

Kevin Kotler

A new filing with the Securities and Exchange Commission showed that Broadfin Capital currently owns 1.35 million shares of Corium International Inc (NASDAQ:CORI), representing 7.66% of common stock outstanding.

Corium International Inc (NASDAQ:CORI) is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal pharmaceutical products. Earlier in March, the company filed a registration statement on Form S-1 with for a proposed initial public offering of its common stock and later it priced its IPO of 6.50 million shares of common stock at a price to the public of $8.00 per share. The underwriters have been granted a 30-day option to purchase up to 975,000 additional shares of common stock at the IPO price.

In AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Broadfin Capital owns 1.43 million shares, the stake amasses 6.55% of the common stock. AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection and MuGard Mucoadhesive Oral Wound Rinse in the United States.

Last month, Jacob Gottlieb’s Visium Asset Management disclosed initiating a 1.6 million position in AMAG Pharmaceuticals Inc. (NASDAQ:AMAG). Adage Capital Management, managed by Phill Gross and Robert Atchinson, held 3.80 million shares of the company at the end of 2013.

In another filing, Broadfin Capital disclosed owning a 5.37% passive stake in La Jolla Pharmaceutical Company (NASDAQ:LJPC). The new position contains around 389,900 common stock shares. La Jolla Pharmaceutical Company (NASDAQ:LJPC) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer.

Earlier this month, the fund revealed a reduced stake in MELA Sciences, Inc (NASDAQ:MELA), owning a total of 9.1 million shares, equal to almost 10% of the common stock, down from over 16% held earlier.

Disclosure: none

Recommended Reading:

Broadfin Capital Initiates Stake in Pernix Therapeutics (PTX)

Kevin Kotler’s Broadfin Capital Initiates Stake in Eleven Biotherapeutics (EBIO) Following Its IPO

Broadfin Capital Initiates a Stake in Retrophin Inc (RTRX) Following Its Listing on NASDAQ

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!